Harpoon Therapeutics’ (NASDAQ:HARP) quiet period is set to end on Wednesday, March 20th. Harpoon Therapeutics had issued 5,400,000 shares in its initial public offering on February 8th. The total size of the offering was $75,600,000 based on an initial share price of $14.00. During Harpoon Therapeutics’ quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
HARP has been the subject of several research reports. Svb Leerink reiterated an “outperform” rating on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. Wedbush initiated coverage on Harpoon Therapeutics in a report on Tuesday, March 5th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Canaccord Genuity initiated coverage on Harpoon Therapeutics in a report on Tuesday, March 5th. They issued a “buy” rating and a $24.00 target price for the company.
Shares of HARP stock opened at $12.28 on Tuesday. Harpoon Therapeutics has a twelve month low of $10.53 and a twelve month high of $17.85.
In other news, major shareholder Bioscience Plc Arix bought 428,571 shares of the stock in a transaction on Tuesday, February 12th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Luke Evnin bought 250,000 shares of the stock in a transaction on Tuesday, February 12th. The stock was purchased at an average price of $14.00 per share, with a total value of $3,500,000.00. The disclosure for this purchase can be found here.
WARNING: “Harpoon Therapeutics Inc’s (HARP) Quiet Period Will Expire Tomorrow” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/03/19/harpoon-therapeutics-incs-harp-quiet-period-will-expire-tomorrow.html.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer.
Featured Story: Understanding the different types of bonds
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.